The Lancet Oncology in conversation with artwork

Shankar Siva on radiotherapy for primary renal cell carcinoma

The Lancet Oncology in conversation with

English - November 28, 2022 23:00 - 8 minutes - 5.87 MB - ★★★★★ - 1 rating
Medicine Health & Fitness Education cancer radiotherapy chemotherapy mrna Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Mark Lawler and Richard Sullivan on the European Groundshot

Next Episode: Sameer Bakhshi on sex disparities in childhood cancer in India

Shankar Siva (Peter MacCallum Cancer Centre, Melbourne, Australia) discusses his Article on 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma.

Read the full article:
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv